Early Bronchodilating Effect of Oxitropium Bromide in Comparison with Ipratropium Bromide

Abstract

The bronchodilating effects of a metered aerosol dose of 40 μg ipratropium bromide and of 200 μg oxitropium bromide are similar 15 min after administration. The bronchodilating activity of ipratropium bromide appears earlier (i.e. 75–90 s after administration) than that of oxitropium bromide but later than that of ibuterol, a β₂-agonist. Ipratropium bromide administered at the dose of 80 μg provokes a bronchodilation about double of that obtained with 40 μg. An adaptation of the usual dosage should be considered.

Efficacy of adding multiple doses of oxitropium bromide to salbutamol delivered by means of a metered-dose inhaler with a spacer device in adults with acute severe asthma

“…The peak bronchodilator effect after administration of oxitropium occurs within 1 to 2 hours. [23][24][25] It was reasonable to expect significant improvement at this time in our study. However, there were no published studies of optimal doses of inhaled oxitropium bromide in combination with β 2 -agonists in patients with acute asthma.…”

Comparison of the Protective Effect Amongst Anticholinergic Drugs on Methacholine-Induced Bronchoconstriction in Asthma

“…Moreover, it was observed that 80 µg of Ipratropium produces a double bronchodilation compared to 40 µg (26), and this dose of Ipratropium (40 µg) resulted sub-optimal for COPD (27). Other dose-response studies, concerning anticholinergic drugs, have put in evidence a greater bronchodilation using progressively increasing doses (8,13,(16)(17)(18).…”

Does oxitropium help in patients with chronic airways obstruction?

“…Ipratropium and a new anticholinergic agent, oxitropium 5–9 have been shown to be anticholinergic bronchodilating agents in patients suffering from airways obstruction in chronic stable asthma and in chronic obstructive pulmonary disease. There are no controlled studies which demonstrate the proportion of such patients who continue to derive clinical benefit as a result of repeated administration of anticholinergic agents, and which show in particular whether long‐term treatment can modify the disease process.…”